Skip to content

Released Aug 4, 2026, before the open

10-Q filed Aug 4, 2026, 35 days after period end · 0001493152-26-035909

Q2 2026 · 10-Q
Revenue$190.10K−69.5% vs Q2 2025+59.2% vs Q1 2026
Net Income-$2.62MN/M vs Q2 2025N/M vs Q1 2026
EPS Diluted-$0.32N/M vs Q2 2025N/M vs Q1 2026
Operating Income-$2,842,246N/M
Operating Cash Flowderived-$3,028,427N/M
Margins · derived
Operating margin-1495.1%−1109.1 pt vs Q2 2025
Net margin-1379.6%−1025.5 pt vs Q2 2025

What the release said

The release

Same quarter

MetricQ2 2026Q2 2025Q2 2024Q2 2023
Revenue$190.10K$622.85K$89.57K$0.00
Net Income-$2.62M-$2.21M-$3.07M-$3.55M
EPS Diluted-$0.32-$0.41-$0.56-$0.68

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Lipocine Inc. · CIK 1535955 · Engraved from SEC EDGAR